Euloge Kpamegan

3.0k total citations · 1 hit paper
11 papers, 1.8k citations indexed

About

Euloge Kpamegan is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Euloge Kpamegan has authored 11 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 4 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Oncology. Recurrent topics in Euloge Kpamegan's work include Renal cell carcinoma treatment (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Treatment and Research (4 papers). Euloge Kpamegan is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Treatment and Research (4 papers). Euloge Kpamegan collaborates with scholars based in United States, Germany and France. Euloge Kpamegan's co-authors include Ken Herrmann, Karim Fizazi, Johann S. de Bono, Michael J. Morris, Oliver Sartor, Bernd J. Krause, Michelle DeSilvio, Tomasz M. Beer, Germo Gericke and Chandler H. Park and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Euloge Kpamegan

11 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Euloge Kpamegan

Since Specialization

Citations

This map shows the geographic impact of Euloge Kpamegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Euloge Kpamegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Euloge Kpamegan more than expected).

Fields of papers citing papers by Euloge Kpamegan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Euloge Kpamegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Euloge Kpamegan. The network helps show where Euloge Kpamegan may publish in the future.

Co-authorship network of co-authors of Euloge Kpamegan

This figure shows the co-authorship network connecting the top 25 collaborators of Euloge Kpamegan. A scholar is included among the top collaborators of Euloge Kpamegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Euloge Kpamegan. Euloge Kpamegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	A VISION Substudy of Reader Agreement on⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for¹⁷⁷Lu-PSMA-617 Radioligand Therapy 2023 ·Journal of Nuclear Medicine ·Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jérémie Calais, James Nagarajah, Wolfgang Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, (unknown), Euloge Kpamegan, Samson Ghebremariam, Taylor L. Benson, Ana M. Catafau, A. Tuba Kendi	12
2	LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) 2023 ·Annals of Oncology ·Oliver Sartor, (unknown), Ken Herrmann, Johann S. de Bono, Neal D. Shore, (unknown), M. J. Crosby, J.M. Piulats Rodriguez, Aude Fléchon, (unknown), Hakim Mahammedi, Guilhem Roubaud, (unknown), Samson Ghebremariam, Euloge Kpamegan, Teri Kreisl, (unknown), (unknown), Michael J. Morris, Karim Fizazi	41
3	Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). 2021 ·Journal of Clinical Oncology ·Michael J. Morris, Johann S. de Bono, Kim N., Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El‐Haddad, Chandler H. Park, Tomasz M. Beer, (unknown), Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Bernd J. Krause, Oliver Sartor, (unknown)	54
4	Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer breakdown → 2021 ·New England Journal of Medicine ·Oliver Sartor, Johann S. de Bono, Kim N., Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El‐Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, (unknown), Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause	1487
5	Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study 2012 ·European Journal of Cancer ·Stéphane Oudard, R. Thiam, Laure Fournier, Jacques Médioni, Michele Lamuraglia, Florian Scotté, Elizabeth Fabre, Dennis Kim, Euloge Kpamegan, Ashok Panneerselvam, C.A. Cuénod	27
6	Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double-blind, placebo-controlled trial 2011 ·Annals of Allergy Asthma & Immunology ·George Bensch, Leon S. Greos, Sandra M. Gawchik, Euloge Kpamegan, Ken B. Newman	16
7	Transfused Myelodysplastic Syndromes (MDS) Patients Have Severe Iron Overload and Relevant Improvements in Iron Burden and Liver Function with Deferasirox Treatment: Results From a Pooled Analysis 2011 ·Blood ·Norbert Gattermann, Peter L. Greenberg, Akio Urabe, Dany Habr, Euloge Kpamegan, John B. Porter	1
8	Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. 2011 ·Journal of Clinical Oncology ·Thomas E. Hutson, Sergio Bracarda, Bernard Escudier, Camillo Porta, Robert A. Figlin, (unknown), Viktor Grünwald, Alain Ravaud, Euloge Kpamegan, Robert J. Motzer	4
9	Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. 2011 ·Journal of Clinical Oncology ·Robert A. Figlin, (unknown), Robert J. Motzer, Thomas E. Hutson, Stéphane Oudard, Camillo Porta, Viktor Grünwald, Alain Ravaud, Euloge Kpamegan	7
10	719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL 2011 ·European Urology Supplements ·Stéphane Oudard, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, J N Thompson, Robert A. Figlin, (unknown), Euloge Kpamegan, Alain Ravaud, Robert J. Motzer	2
11	Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma 2010 ·American Journal of Respiratory and Critical Care Medicine ·Dorothy A. White, Philippe Camus, Masahiro Endo, Bernard Escudier, Emiliano Calvo, Hideyuki Akaza, Hirotsugu Uemura, Euloge Kpamegan, Andrea Kay, Matthew Robson, Alain Ravaud, Robert J. Motzer	156

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact